Beta-blockers have no impact on cocaine-related chest pain

β-blockers have no impact on cocaine-related chest pain

(HealthDay)—For patients with cocaine-associated chest pain, there are no differences in outcome for those treated with or without β-blockers, according to a study published in the June 1 issue of The American Journal of Cardiology.

Zaher Fanari, M.D., from the Christiana Care Health System in Newark, Del., and colleagues compared in-hospital outcomes for patients with cocaine-associated chest pain who were treated with and without β-blocker therapy. After adjustment for clinical characteristics, propensity scores were used to assess the independent correlation between β-blocker use and the composite primary end point of myocardial infarction, stroke, ventricular arrhythmia, or all-cause mortality.

The researchers found that β-blockers were used in 44 percent of the 376 patients with cocaine-related chest pain. Patients treated with β-blockers were more likely than those with no β-blockers to describe anginal chest pain, have known , and receive other antiatherosclerotic therapies. Patients treated with β-blockers experienced similar peak troponin levels, individual adverse events, and rates of the composite primary end point (15.9 versus 12.3 percent; P = 0.32), in spite of having higher risk clinical characteristics. After propensity score analysis, the primary end point was similar compared with patients not receiving β-blockers (odds ratio, 1.37; P = 0.42), including specific comparisons of beta-1 selective (odds ratio, 1.83; 95 percent confidence interval, 0.79 to 4.24) and nonselective (odds ratio, 0.90; 95 percent confidence interval, 0.33 to 2.42) β-blockers.

"No differences in outcomes were observed between treated versus not treated with β-blocker therapy in the setting of cocaine-related ," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Vitamin K antagonist plus clopidogrel feasible for PCI

Sep 19, 2014

(HealthDay)—Vitamin K antagonists (VKA) combined with clopidogrel may be a better alternative to triple anticoagulant therapy in patients on long-term VKA undergoing percutaneous coronary intervention (PCI) ...

How pneumonia bacteria can compromise heart health

Sep 19, 2014

Bacterial pneumonia in adults carries an elevated risk for adverse cardiac events (such as heart failure, arrhythmias, and heart attacks) that contribute substantially to mortality—but how the heart is ...

User comments